ArticleBMC cancer2026
CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation and nutritional status are increasingly recognized as prognostic determinants in glioblastoma (GBM). The CRP–albumin–lymphocyte (CALLY) index integrates inflammatory and immune-nutritional components, yet its prognostic value in GBM remains unclear.
aimsThis study compared the prognostic performance of CALLY with other inflammation-based indices, including NLR, SII, SIRI, PIV, and NLPR.
methodsNinety-two patients with histologically confirmed GBM treated with maximal safe resection followed by standard concurrent radiotherapy and temozolomide (Stupp protocol) were retrospectively analyzed (2019–2025). Baseline hematologic indices were calculated from pre-treatment blood tests. Survival outcomes were assessed using Kaplan–Meier and Cox regression analyses. Prognostic discrimination was quantified with time-dependent ROC curves and bootstrap-corrected AUCs at 6- and 12-month horizons.
resultsMedian overall survival (OS) and progression-free survival (PFS) were 14 months and 6 months, respectively. A CALLY cut-off of 1.92 best discriminated outcomes: median OS 21 months vs. 10 months and PFS 14 months vs. 4 months (p < 0.001). CALLY achieved the highest AUCs for 12-month PFS (0.915) and OS (0.891), maintaining significance after internal validation. In multivariable analysis, low CALLY independently predicted poorer OS (HR = 3.83; p = 0.002) and PFS (HR = 7.69; p < 0.001). SIRI and PIV ranked second and third in discriminative performance.
conclusionsIn this single-centre retrospective cohort, lower baseline CALLY scores were associated with inferior survival outcomes in patients with GBM. These findings suggest that CALLY may represent a potentially useful inflammation-based prognostic marker. However, given the exploratory design and limited sample size, prospective multicentre studies are required to validate these results before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.